Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque (DENRENIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02471729
Recruitment Status : Unknown
Verified October 2016 by Institute Arnault Tzanck, France.
Recruitment status was:  Not yet recruiting
First Posted : June 15, 2015
Last Update Posted : October 19, 2016
Sponsor:
Collaborator:
Abbott Medical Devices
Information provided by (Responsible Party):
Institute Arnault Tzanck, France

Brief Summary:

Management of chronic heart failure (CHF) is a major public health problem. It is associated with high mortality, frequent hospitalization and represents a large cost to the health care system. Both pharmacological and non-pharmacological intervention haven't shown to be effective in reducing morbidity and mortality of these patients when able to modulate the activity of neuro-hormonal systems among them the sympathetic nervous system. Recent data have emphasized the potential role of sympathetic renal denervation in patient with hypertension. CHF per se but even more CHF associated with comorbity lead to significant increase level of sympathetic tone. This is largely induced by autonomic dysfunction such as chemo or baroflex abnormalities. These patients usually suffer from conditions which do not allow upgrading and adapting drugs to their sympathetic condition. Hence CHF patient with chronic kidney disease, anemia or both have markedly high sympathetic activity and cannot be exposed to higher level of RAS Blockers or beta blocker due to their renal dysfunction, they thus remain with an elevated sympathetic activity worsening symptoms and prognosis. Chronic heart failure affects around 100 million people worldwild imposing a significant burden on health care system throughout the world. Even though symptoms are improved by heart failure therapy, they remain significantly disabling for many patients. Chronic over activation of the sympathetic nervous system is a major component of heart failure and involves efferent and afferent pathways between brain and many organs. A new therapy directly targeting nerve traffic-renal artery denervation- has been shown to be effective in drug resistant hypertension, with an average drop in blood pressure of 33/12 mm hg.

The cardiologists team of the private hospital Arnault Tzanck is willing therefore to conduct a study in 12 patients with chronic systolic heart failure undergoing bilateral renal denervation with an intensive protocol of observation and assessment compring a 3 day hospital stay post procedure 3 and 6 months of regular outpatient follow-up.


Condition or disease Intervention/treatment Phase
Chronic Heart Failure Device: EnligHTN™ Renal Denervation System Phase 1 Phase 2

Detailed Description:

Renal denervation is a new interventional cardiology technique that involves using a catheter and a femoral artery, inserting an RF probe that will destroy the nerve fibers in contact with the wall of the renal artery with a very small electric current.

The method utilizes the energy emitted by a miniaturized device positioned at the end of a catheter. This catheter is positioned in the arteries going to the kidneys.

Sympathetic overactivation, is reduced by renal denervation in drug-resistant hypertension. Several studies conducted in patients without heart failure showed that renal denervation reduces left ventricular hypertrophy beyond its only effect on blood pressure.

Chronic over activation of the sympathetic nervous system is a major component of heart failure and involves efferent and afferent pathways between brain and many organs.

The purpose of this Clinical investigation is to evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with chronique heart failure.

All patients will be on stable maximal tolerated pharmacological therapy for HFC prior to denervation.

After the procedure all patients will be monitored as inpatients for 3 days so that hemodynamic disturbances could be identified. Baseline measurements, including BNP, echo Doppler VO2 and six minutes walk test will be repeated before discharge from hospital.

After discharge patients will be followed up weekly for 4 weeks and then after 3 and 6 months. At the end of the study, bnp, echo Doppler Vo2 and six minutes walk test will be repeated, they also will be asked to categorize themselves as feeling worse, the same, or better in comparison to their preprocedural state.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation à Six Mois du système de dénervation rénale Chez Les Patients Atteints d'Insuffisance Cardiaque
Study Start Date : January 2017
Estimated Primary Completion Date : September 2017
Estimated Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Renal Denervation
patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
Device: EnligHTN™ Renal Denervation System
The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
Other Names:
  • EnligHTN™ Renal Artery Ablation Catheter
  • EnligHTN™ RF Generator
  • EnligHTN™ Guiding Catheter




Primary Outcome Measures :
  1. Significant improvement of the 6 minutes walk test [ Time Frame: 6 months ]
    The primary efficacy end point is the assessment at 6 months post renal denervation of the improvement in symptomatology as BNP level or VO2 max or pharmacological therapy from baseline


Secondary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: 5 months ]
    Assessment of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation Renal function change based on eGFR

  2. Quality of life evaluated by EQ-5D. 1 [ Time Frame: before intervention and after 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable chronic heart failure
  • NYHA III-IV
  • LV EF <35 assessed by ultrasound
  • EGFR> 45ml / min / 1.73m2
  • Optimal therapeutic treatment
  • IMC : 17-24

Exclusion Criteria:

  • significant renovascular abnormalities such as renal artery stenosis> 30%.
  • renal angioplasty history, renal denervation, stent placement
  • hemodynamically significant valvular heart disease
  • an active systemic infection.
  • renal artery of <4 mm.
  • coagulation abnormalities.
  • kidney transplant or is waiting for a kidney transplant.
  • life expectancy of less than 12 months (seatle score).
  • femoral-iliac atherosclerotic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02471729


Contacts
Layout table for location contacts
Contact: Jean Louis LLORET, MD 33 (0)4.97.16.65.17 jl.lloret@tzanck.org

Locations
Layout table for location information
France
Clinique Plein Ciel Not yet recruiting
Mougins, Alpes Maritimes, France, 06254
Contact: Jean Louis LLORET, MD         
Sponsors and Collaborators
Institute Arnault Tzanck, France
Abbott Medical Devices
Investigators
Layout table for investigator information
Principal Investigator: Jean Louis LLORET, MD Private hospital Mougins Arnault Tzanck

Layout table for additonal information
Responsible Party: Institute Arnault Tzanck, France
ClinicalTrials.gov Identifier: NCT02471729     History of Changes
Other Study ID Numbers: P010215
First Posted: June 15, 2015    Key Record Dates
Last Update Posted: October 19, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Institute Arnault Tzanck, France:
Cardio-Renal Syndrome
Chronic Heart Failure
Renal Denervation
Sympathetic activation
Heart Failure
Cardiovascular Diseases
Heart Diseases

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases